Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?

Clinical Genitourinary Cancer
Oktay BozkurtMetin Ozkan

Abstract

We investigated the clinicopathological features in patients with recurrent renal cell carcinoma (RCC) within 5 years or more than 5 years after nephrectomy and determined predictors of overall survival (OS) and progression-free survival (PFS) after disease recurrence in the administration of first-line sunitinib in the treatment of metastatic RCC (mRCC). In this study we enrolled 86 Turkish patients with mRCC who received sunitinib. Univariate analyses were performed using the log rank test. Fifty-six patients (65%) were diagnosed with disease recurrence within 5 years after radical nephrectomy (early recurrence) and 30 patients (35%) were diagnosed with recurrence more than 5 years after radical nephrectomy (late recurrence). Fuhrman grade was statistically significantly different between the 2 groups (P = .013). The late recurrence patients were significantly associated with the Memorial Sloan Kettering Cancer Center favorable risk group compared with patients with early recurrence (P = .001). There was a statistically significant correlation between recurrence time and the rate of objective remission (ORR) (the late recurrence group vs. the early recurrence group: 43.3% vs. 14.3%, respectively; P = .004). From the time of d...Continue Reading

References

Dec 19, 2003·The Urologic Clinics of North America·Nicolette K JanzenArie S Belldegrun
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael B AtkinsLaura King
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ronald M BukowskiPaul Elson
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tarek M MekhailRonald Bukowski
May 10, 2005·Diagnostic Cytopathology·Maria Sironi, Gianni Tunesi
Jun 22, 2005·European Urology·Hans-Stefan HofmannRolf-Edgar Silber
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Dec 13, 2005·The New England Journal of Medicine·Herbert T Cohen, Francis J McGovern
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frede Donskov, Hans von der Maase
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Nov 7, 2009·Clinical Genitourinary Cancer·Ana M Molina, Robert J Motzer
Feb 24, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael S AnglesioDavid D Bowtell

❮ Previous
Next ❯

Citations

Nov 20, 2015·International Journal of Urology : Official Journal of the Japanese Urological Association·Kouji Izumi
Nov 4, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jie ZhuXu Zhang
Feb 3, 2021·International Journal of Urology : Official Journal of the Japanese Urological Association·Chan Ho LeeUNKNOWN Korean Renal Cancer Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.